
==== Front
Cancer Rep (Hoboken)
Cancer Rep (Hoboken)
10.1002/(ISSN)2573-8348
CNR2
Cancer Reports
2573-8348
John Wiley and Sons Inc. Hoboken

10.1002/cnr2.70006
CNR270006
CNR2-24-0435.R1
Review
Review
Therapeutic Potential of Terpenoids in Cancer Treatment: Targeting Mitochondrial Pathways
Guo Jianxin https://orcid.org/0009-0008-7599-4149
1
Huang Ming 1
Hou Shuang 1
Yuan Jianfeng 1
Chang Xiaoyue 1
Gao Shuang 1
Zhang Zhenhan 1
Wu Zhongbing 1 19001631@hebmu.edu.cn

Li Jing 1 2 lijing@hebmu.edu.cn

1 College of Integrated Chinese and Western Medicine Hebei Medical University Shijiazhuang China
2 The Fourth Hospital of Hebei Medical University Shijiazhuang China
* Correspondence:
Zhongbing Wu (19001631@hebmu.edu.cn)
Jing Li (lijing@hebmu.edu.cn)

05 9 2024
9 2024
7 9 10.1002/cnr2.v7.9 e7000630 7 2024
22 5 2024
11 8 2024
© 2024 The Author(s). Cancer Reports published by Wiley Periodicals LLC.
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background

In recent decades, natural compounds have been considered a significant source of new antitumor medicines due to their unique advantages. Several in vitro and in vivo studies have focused on the effect of terpenoids on apoptosis mediated by mitochondria in malignant cells.

Recent findings

In this review article, we focused on six extensively studied terpenoids, including sesquiterpenes (dihydroartemisinin and parthenolide), diterpenes (oridonin and triptolide), and triterpenes (betulinic acid and oleanolic acid), and their efficacy in targeting mitochondria to induce cell death. Terpenoid‐induced mitochondria‐related cell death includes apoptosis, pyroptosis, necroptosis, ferroptosis, autophagy, and necrosis caused by mitochondrial permeability transition. Apoptosis and autophagy interact in meaningful ways. In addition, in view of several disadvantages of terpenoids, such as low stability and bioavailability, advances in research on combination chemotherapy and chemical modification were surveyed.

Conclusion

This article deepens our understanding of the association between terpenoids and mitochondrial cell death, presenting a hypothetical basis for the use of terpenoids in anticancer management.

cancer
cell death
mitochondrial
terpenoids
National Natural Science Foundation of China 10.13039/501100001809 8227150213 Hebei Province Traditional Chinese Medicine Scientific Research Subjects Programme2024110 Science Research Project of Hebei Education DepartmentBJK2024036 Natural Science Foundation of Hebei Province 10.13039/501100003787 H2023206137 source-schema-version-number2.0
cover-dateSeptember 2024
details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:6.4.8 mode:remove_FC converted:05.09.2024
Funding: This study was supported partially by the National Natural Science Foundation of China (8227150213), Science Research Project of Hebei Education Department (BJK2024036), Natural Science Foundation of Hebei Province (H2023206137), and Hebei Province Traditional Chinese Medicine Scientific Research Subjects Programme (2024110).
==== Body
pmcAbbreviations

Akt AKT serine/threonine kinase

ATO arsenic trioxide

ATP adenosine triphosphate

BA betulinic acid

BAD BCL2 associated agonist of cell death

Bax BCL2‐associated X

BCL‐2 B‐cell lymphoma‐2

CAV‐1 caveolin‐1

CDDP chemotherapeutic agent cisplatin

DHA dihydroartemisinin

ERK extracellular regulated protein kinases

ERS endoplasmic reticulum stress

GPX4 glutathione peroxidase 4

GSH glutathione

HA hyaluronic acid

HK‐II hexokinase II

IAPs inhibitors of apoptosis proteins

IKKβ Inhibitor of kappa B kinase

JNK c‐Jun N‐terminal kinase

JNK c‐Jun N‐terminal kinase

MAPK mitogen‐activated protein kinase

Mcl‐1 myeloid cell leukemia‐1

MLKL mixed lineage kinase domain‐like protein

MMP mitochondrial membrane potential

mtor mammalian target of rapamycin

Myc MYC proto‐oncogene, BHLH transcription factor

NDDS nanoscale drug delivery systems

NDUFS3 NADH: Ubiquinone Oxidoreductase Core Subunit S3

NF‐kB nuclear factor‐kappa B

NRF2 nuclearrespiratoty factor 2

OA oleanolic acid

Ori oridonin

OSCC oral squamous cell carcinoma

OXPHOS oxidative phosphorylation

P38 P38 mitogen‐activated protein kinase

PARP poly ADP‐ribose polymerase

PDAC pancreatic ductal carcinoma

PI3K phosphatidylinositol 3‐hydroxy kinase

PINK1 PTEN induced putative kinase 1

PTL parthenolide

Ras rat sarcoma

RIP1 receptor interacting protein 1

RIPK1 receptor interacting serine/threonine kinase 1

RIPK3 receptor interacting serine/threonine kinase 3

RNA ribonucleic acid

ROS reactive oxygen species

SDHB succinate dehydrogenase complex iron sulfur subunit B

SIRT‐1 silent information regulator‐1

SLC7A11 solute carrier family 7 member 11

STAT signal transducer and activator of transcription

TPL triptolide

TPS terpene synthase

TrxR thioredoxin reductase

UQCRFS1 ubiquinol‐cytochrome c reductase, rieske iron–sulfur polypeptide 1

1 Introduction

Cancer, the leading cause of death worldwide, has long been a major public health concern. The American Cancer Society estimates 2 001 140 new cancer cases and 611 720 cancer deaths to occur in the United States by 2024 [1]. With a growing and aging population, cancer treatment is currently more challenging than ever [2, 3, 4].

Unlike well‐regulated healthy cells, tumor cells require a significant amount of energy to sustain their rapid growth [5, 6]. Mitochondria, a junction in the metabolic pathways of glucose, glutamine, and lipids, and the powerhouse in eukaryotic cells can meet the energy demand of tumor cells [7, 8]. Paradoxically, mitochondria are a key organelle in programmed cell death [9], regulating cell death through various mechanisms, such as ferroptosis, mitophagy, NETosis, entosis, pyroptosis, necroptosis, parthanatos, apoptosis, clockophagy, alkaliptosis, autosis, and oxeiptosis [10, 11, 12, 13]. These mitosome‐dependent cell death pathways can be programmed to treat cancer [14, 15, 16].

Natural compounds provide unique advantages in cancer treatment due to their structural diversity and multifunctional activities [17, 18, 19, 20]. Several studies have revealed that terpenoids are effective in treating cancer through the mitochondria‐dependent cell death pathways [21, 22, 23, 24, 25]. Terpenoids are the most extensive category of naturally occurring chemical substances, including over 40 000 chemicals. They are frequently used in the taste, perfume, chemical, and medicinal sectors [26, 27, 28]. Terpenoids may be categorized into several groups based on their structure, including tetraterpenoids, diterpenoids, monoterpenoids, hemiterpenoids, sesquiterpenoids, sesterterpenoids, triterpenoids, and polyterpenoids [29]. In recent years, terpenoids have been widely investigated for their potential applications in human pathophysiology due to their diverse biological activities [30, 31]. An increasing number of pharmacological investigations have reported the advantages of terpenoids in tumor therapy [32], and further studies of these compounds may help develop antitumor drugs. In this review article, we focused on natural terpenoids that exert anticancer activity through the mitochondrial cell death pathway. In addition, we selected three terpenoids that our extensive literature search revealed to be the most studied in cancer‐related mitochondrial cell death. In particular, we investigated two diterpenoids (oridonin [Ori] and triptolide [TPL]), two sesquiterpenoids (dihydroartemisinin [DHA] and parthenolide [PTL]), and two triterpenoids (betulinic acid [BA] and oleanolic acid [OA]) as well as some of their derivatives (Figure 1).

FIGURE 1 Chemical structures of selected terpenoids and their derivatives.

2 Diversity of Terpenoids and Their Sources

Terpenoids are an extensive library of compounds for anticancer drug screening [33]. In general, terpenoids are derived from isoprene units. The condensation of two isoprenyl units results in monoterpene, three units form a sesquiterpene, four units form a diterpene, and six units form a triterpene; the isoprenyl units involved in the condensation process are usually in the form of diphosphates [34]. Terpenoids are diverse for several reasons. First, variation in the terpene skeleton, whose synthesis is catalyzed by terpene synthase (TPS), can lead to changes in terpenoids [35, 36]. Second, individual amino acid changes in TPS can cause drastic alterations in the resulting terpenoid structure [37]. Moreover, mutation in TPS genes is facilitated by their existence in families of 30–100 genes [38].

Studies have revealed that terpenoids are ancient compounds that had a part in the early lifeform evolution [39]. Various range of organisms, such as terrestrial plants and animals [40, 41], microorganisms [42, 43], marine plants and animals [44, 45], and even some organisms living in the harsh environment of the Arctic and Antarctica, synthesize terpenoids [46]. However, our demand for the more potent varieties remains to be met despite the large supply of naturally generated terpenoids [47, 48]. Industrial production of terpenoids can take one of three possible routes. The most direct approach is simply extraction from natural resources, including plants and animals [49, 50, 51]. Another possibility is chemical synthesis [52, 53]. However, the former is no longer considered a viable option due to environmental concerns. In addition, chemical synthesis is infeasible due to the structural complexity of the products [54]. The third approach—microbial cell factory—now holds more promise due to rapid advances in synthetic biology and metabolic engineering. These include engineered cyanobacteria [55], engineered phototrophic bacteria [56], engineered yeast [57], and Yarrowia lipolytica cell factories [58]. Microbial cell factories, known for their robustness, safety, and sufficient supply of precursors, achieved de novo synthesis of terpenoids. This offers a promising and environmentally friendly alternative to natural plant extraction and traditional terpenoid supply methods, such as chemical synthesis. This advancement paves the way for the use of terpenoids as antineoplastic drugs.

3 Sesquiterpenoids in Mitochondrial Cell Death

3.1 DHA in Mitochondrial Cell Death

DHA is the main active compound in the sesquiterpenoid artemisinin. It was initially used in treating malaria upon its discovery. DHA exerts its antimalarial effects by damaging the membranes of the digestive vacuoles and mitochondria of the parasite [59]. Investigations on the metabolism of drugs have demonstrated DHA as the primary active form of many artemisinin derivatives, including artesunate, artemether, and arteether. This indicates that DHA is an active component responsible for the effects of these medications [60, 61, 62]. In addition to antimalarial effect, DHA has demonstrated significant antitumor activity both in vitro and in vivo [63, 64], which is believed to involve mitochondria‐related cell death.

DHA has impeded cell growth and prompted ferroptosis in lung malignancy and leukemia cells by disrupting mitochondrial functions. Specifically, DHA has been revealed to disturb the membrane potential of the mitochondria, increase cytoplasmic levels of reactive oxygen species (ROS), and decrease the key protein expression related to Fe‐S cluster binding within mitochondrial complexes, namely NDUFS3, SDHB, and UQCRFS1, as well as SLC7A11, which is an iron‐dependent cell death pivotal modulator [65, 66]. The synergistic application of DHA and the chemotherapeutic agent cisplatin (CDDP) disrupts mitochondrial homeostasis in pancreatic ductal carcinoma cells. This disruption is evidenced by mitochondrial morphology changes, respiratory capacity reduction, ATP production decrease, and mitochondrial ROS accumulation. These effects cause the free iron and lipid peroxidation buildup, ultimately causing ferroptosis [67]. Interestingly, DHA administration in combination with CDDP induced significant mitochondrial autophagy in oral squamous cell carcinoma (OSCC) [68]. Meanwhile, DHA alone caused mitochondrial autophagy in liver carcinoma cells (HepG2215) and gastric cancer cells (SGC7901/DDP) [69, 70]. Notably, autophagy has a dual role of cytoprotection and cytotoxicity, the specific role of which depends on the kind of tumor cell and stress level [71]. Wu et al. revealed that applying DHA to lung cancer cells (A549) reduced radiation‐induced mitochondrial autophagy and radioresistance [72]. The tumor‐suppressing effects of DHA are more prominently observed in mediating mitochondrial apoptosis in addition to inducing ferroptosis and mitochondrial autophagy. Investigations have revealed that DHA causes mitochondrial apoptosis in various human malignancy cell lines, including ovarian cancer (IOSE80, SKOV3, A2780, OVCAR3, and TOV112D), melanoma (B16F10), breast cancer (4T1), lung cancer (A549), bladder cancer (T24), and neuroblastoma (SH‐SY5Y) [73, 74, 75, 76, 77, 78]. Interestingly, a clinical study revealed that apoptosis was present in 67% of the tumor cells of patients with colorectal cancer in the artesunate group. Additionally, Ki67 expression decreased and CD31 expression increased in patients in the artesunate group [79].

Scientists have developed various nanoscale drug delivery systems to accommodate the poor stability of DHA, reduced solubility of water, and short plasma half‐life [80]. These include polymer‐based nanoplatforms for DHA–hyaluronic acid conjugates [81], lipid‐based nanoplatforms for R8 modified epirubicin‐DHA liposomes [82], metal–organic framework‐based nanoplatforms for loading DHA [83], and inorganic nanoparticle‐based platforms for delivering DHA and transferrin [84].

3.2 PTL in Mitochondrial Cell Death

PTL is a sesquiterpene lactone found in the branches of the plant Tanacetum parthenium, and it demonstrates potent anticancer and anti‐inflammatory activities [85]. Intrigued by its undeniable anticancer effect, many scientists have been trying to unravel the underlying mechanism.

Investigations have revealed that PTL induces cancer cell death primarily by affecting mitochondria [86]. In hepatocellular carcinoma stem cells, PTL induces ROS production, decreases mitochondrial membrane potential (MMP) and oxidative phosphorylation (OXPHOS) levels, stimulates cytosolic stop in the G1 phase, and induces apoptosis [87]. Interestingly, in hepatocellular carcinoma cells (HEK293T, HepG2, MHCC 97H, and Huh7), PTL administered in combination with arsenic trioxide (ATO) improved cytoprotective autophagy via the PI3K/Akt/mTOR pathway as well as induced mitochondrial apoptosis through the classical pathway [88]. This observation hints at a complex association between apoptosis and autophagy, with the latter analogous to a double‐edged sword whose inhibition can potentially improve the therapeutic effect of PTL and ATO [89]. Autophagy has demonstrated the ability to suppress apoptosis. Reports have indicated mitophagy as the main mechanism underlying this phenomenon, and after mitochondrial damage, proapoptotic factors increase the permeability of the membranes of the affected mitochondria, thereby activating autophagy, which eliminates damaged mitochondria and reduces the chance of apoptosis [90]. In addition, autophagy activates apoptosis in certain special cases. In particular, the formation of autophagic vesicles may potentially trigger caspase activation. Moreover, autophagy breaks down inhibitors of apoptosis proteins (IAPs) [91, 92]. PTL in cells of hepatocellular carcinoma modifies their antioxidant microenvironment via thiol changes, making the tumor cells more sensitive to increased ROS levels, thereby causing lipid peroxidation and eventually ferroptosis [93].

Another investigation revealed that PTL has triggered apoptosis in all lymphatic tumor cell lines, including KOPN‐8, Farage, Raji, 697, NCI‐H929, CEM, and MOLT‐4. Apoptosis was accompanied by a significant increase in ROS as well as moderately low glutathione and MMP levels. Furthermore, PTL effectively suppressed the stimulation of nuclear factor kappa B (NF‐kB) in CEM and MOLT‐4 cell lines [94]. An in vitro and an in vivo model of triple‐negative breast malignancy confirmed similar outcomes [95]. NF‐κB affects mitochondrial respiration and mitochondrial dynamics, whereas mitochondria respond by promoting NF‐κB activation. The interaction between the two sustains tumor cell survival and development [96]. Additionally, PTL targets multiple key proteins that act on the NF‐κB signaling pathway, such as receptor‐interacting protein 1 (RIP1) [95, 97], NF‐κB inhibitor (IκB), and kappa B kinase inhibitor (IKKβ) [98]. This provides a new perspective on the clinical application of PTL in tumor treatment.

4 Diterpenoids

4.1 Oridonin in Mitochondrial Cell Death

Ori is a biologically active diterpenoid extracted from Isodon rubescens (Hemsl.) H. Hara with potent antitumor properties [99]. Ori induces apoptosis and necroptosis in acute myeloid leukemia cells [100]. Reports indicated that apoptosis caused by Ori, which depends on mitochondria, is associated with AKT suppression via phosphorylation [101, 102, 103]. AKT, a serine/threonine kinase, has a vital role in several essential physiological mechanisms, such as survival, growth, invasion, and apoptosis. It has exhibited potential as a target for cancer treatment [104]. Ferroptosis has been identified as another mode of Ori‐induced malignancy cell death. A2, a derivative of Ori, decreased MMP, lowered BCL‐2 levels, promoted the PARP and Caspase‐3/9 proteins cleavage, and induced mitochondria apoptosis in vitro and in vivo models of gastric malignancy. This increased intracellular ROS, reduced GPX4, catalyzed lipid peroxides reduction, and eventually caused ferroptosis [105].

To enhance the antitumor impact of Ori and explore its pathway of action, synthetic derivatives have become a common tool [106]. Ni et al. created and produced a range of Ori spirolactone‐type and enmein‐type compounds (Ori 7K) with various C‐14 hydroxyl substitution levels [107]. Another study investigated a series of Ori derivatives, such as acetylated derivatives (Ori 20) [108]. Interestingly, both studies revealed that Ori derivatives caused apoptosis in tumor cells by increasing intracellular ROS levels and depolarizing MMP. The IC50 values of these derivatives revealed a substantial decrease compared with Ori.

Furthermore, Ori has exhibited significant efficacy when used in combination with conventional antitumor medicines in clinical settings. In particular, the combined application of Ori with homoharringtonine downregulated c‐KIT and its associated downstream signaling pathways (STAT, MAPK, and PI3K), thereby reducing MMP, decreased Mcl‐1 levels, and Caspase‐3 activation, ultimately causing cellular apoptosis [109]. This emphasizes the significance of using combination therapies for cancer management. The synergistic effect of Ori in combination with chemotherapy and targeted therapy has improved the cancer cells' drug sensitivity, elevated cellular mitochondrial apoptosis, reduced drug dosage, and mitigated side effects [110, 111]. Furthermore, the literature indicates that Ori's anticancer properties may be related to its regulation of mitochondrial pyroptosis and have been used as a new targeted therapeutic approach [112].

4.2 TPL in Mitochondrial Cell Death

TPL, a diterpenoid [113], is the predominant pharmacologically active component of Tripterygium wilfordii Hook. F. It is used in treating inflammatory [114, 115, 116], autoimmune [117, 118], renal [119, 120], and neurological diseases [121, 122] as well as tumors [123, 124].

Compelling evidence from studies using ex vivo and in vivo tumor models has indicated that TPL induces apoptosis in colorectal, non‐small cell lung, and pancreatic cancers and acute myeloid leukemia cells via the pathway of mitochondrial apoptosis [125, 126, 127, 128]. Both in vitro and in vivo models of malignant cells indicated that TPL significantly inhibited the NF‐κB signaling pathway, SIRT‐1/CAV‐1 axis, and phosphorylation of RNA pol II; elevated mitochondrial fission and ROS; reduced MMP; and induced changes in apoptosis‐related proteins, such as Caspase‐9, Caspase‐3, Bcl‐2, Bax, C‐PARP, c‐Myc, and Mcl1. In head and neck tumor cells, TPL triggers apoptosis of the mitochondria by inhibiting mitochondrial hexokinase II (HK‐II), a critical metabolic enzyme in the glycolytic pathway, thereby activating the apoptosis‐associated BAD/BAX‐Caspase 3 pathway [129]. In addition, TPL‐induced suppression of NRF2 expression causes ferroptosis in leukemia cells [130]. Interestingly, in in vitro head and neck tumor cells, ferroptosis was considered to be caused by TPL in synergy with erastin, which inhibited the NRF2/SLC7A11 axis [129]. NRF2 plays a crucial role in reducing lipid peroxidation and iron‐induced cell death, indicating that targeting NRF2 with TPL may have clinical implications [131]. In addition, a Phase I study involving patients with advanced gastrointestinal tract cancer initially assessed the pharmacokinetics and antitumor activity of Minnelide, a water‐soluble prodrug of TPL [132]. This study revealed that Minnelide was converted to TPL and reached its peak concentration 30 min after infusion, with a half‐life of ~1 h, a reduction in mean target lesion tumor density in 16 out of 28 (57.1%) patients, and a disease control rate lasting from 2 to 6 months in 14 out of 28 (50%) evaluable patients.

However, the medical efficacy of TPL is constrained by its organ toxicity, particularly hepatotoxicity [133]. Research indicates that the hepatotoxic effects of TPL may be associated with mitochondrial oxidative stress [134], excessive mitochondrial autophagy [135, 136], and mitochondrial apoptosis [137]. Recent studies have revealed that mitochondria‐targeting derivatives of TPL can mitigate their renal and hepatic toxicity [138], thereby bolstering the argument for clinical applications of TPL as an antitumor drug. However, additional investigation is warranted to confirm the dual effects and underlying pathways of TPL on mitochondrial death in tumor cells.

5 Triterpenoids

5.1 BA in Mitochondrial Cell Death

BA, a pentacyclic triterpenoid primarily detected in birch, sycamore, and other plants [139, 140], has revealed a range of biological features such as antitumor [141], anti‐inflammatory [142], neuroprotective [143], and antioxidant effects [144]. Recently, several studies have revealed that the anticancer mechanism of BA correlates with its cellular mitochondrial apoptosis induction, which applies to a range of human cancer cell lines, including laryngeal cancer cells originating from the head and neck region (AMC‐HN‐8), gastrointestinal malignancy cholangiocarcinoma cells (NOZ), colorectal cancer cells (HCT116), ovarian cancer cells (A2780, SW480, and DLD‐1), and bladder cancer cells (T24, UMUC‐3, and 5637) [145, 146, 147, 148, 149]. These research results indicate that BA‐induced apoptosis is initiated through the intrinsic pathways mediated by mitochondria, as manifested as Caspase‐3/8/9 activation, PARP cleavage, Bax accumulation in mitochondria, MMP disruption, and ROS level elevation [147, 149]. However, Kim et al. revealed that BA‐mediated mitochondrial apoptosis in human bladder cancer cells had no effect on intracellular ROS levels [149], and this result was corroborated by Sharma and Kumar [150]. However, the mechanism of this ROS‐independent pathway of apoptosis warrants further investigation. Yao et al. [151] revealed that B5G1, a BA derivative, triggered apoptosis in malignancy cells that are resistant to many drugs, HepG2/ADM and MCF‐7/ADR, while activating the non‐canonical mitophagy pathway, PINK1/Parkin. This pathway facilitated mitochondrial autophagy in the cells, acting as a protective mechanism against apoptosis. This indicates that PINK1/Parkin‐mediated mitochondrial autophagy suppression increases drug sensibility in malignancy cells that are resistant to many drugs.

5.2 OA in Mitochondrial Cell Death

OA, a pentacyclic triterpenoid, chemically known as 3β‐hydroxy‐olean‐12‐en‐28‐oic acid, is detected both in its free form and as the glycosidic ligand of triterpenoid saponins. It has been identified in over 1620 species of edible and medicinal plants [152, 153, 154]. OA demonstrates various physiological properties, such as anti‐inflammatory [155, 156], hypoglycemic [157, 158], and anticholestatic effects [159]; moreover, it offers protection against renal damage [160]. Furthermore, OA exhibits notable anticancer properties in various tumor types through mitochondrial autophagy, apoptosis, and ferroptosis [161, 162, 163, 164]. Both in vivo and in vitro experiments have revealed that OA triggers autophagy and apoptosis mediated by mitochondria in hepatocellular carcinoma. This action may be associated with the suppression of NF‐κB, Akt, and mTOR pathways [165, 166].

Recent research has revealed that OA may cause mitochondrial apoptosis in tumor cells by activating the P38 pathway. OA suppresses the function of JNK [162] and modulates P38 activity in this apoptotic signaling cascade [167], thereby regulating downstream targets FOXO3a/Sirt6 [164]. This ultimately disrupts MMP, reduces ROS, releases cytochrome c, upregulates caspases‐3/7/8/9 and Bak, and downregulates Bcl‐2 levels [161, 162]. Furthermore, the OA derivative (OA 4b) suppresses thioredoxin reductase (TrxR) activity and induces endoplasmic reticulum stress through ROS activation, ultimately causing apoptosis in cancerous cells [168].

Studies have revealed that mitochondria are crucial in initiating apoptosis and are recognized as both a source and target of ROS [169]. OA partakes in multiple mitochondria‐mediated pathways, some involving ROS [170, 171] and others independent of ROS, in promoting tumor cell apoptosis [161]. This indicates that the antitumor effect of OA is not entirely dependent on the oxidation state, which aligns with the “double‐edged sword” characteristic of ROS.

Mitochondria are potential targets for cancer therapy. Several studies have developed and synthesized OA derivatives (5b, 6c, and aridanin) that specifically target mitochondria. Such mitochondria‐targeting derivatives selectively destroy malignancy cells by inducing apoptosis, ferroptosis, autophagy, and necrotic cell death [163, 172, 173] through a mechanism primarily involving the PI3K‐Akt pathway [174] (Tables 1 and 2).

TABLE 1 In vitro studies of terpenoids as inducers of mitochondrial death in tumor cells are shown in the table.

Terpenoids	Plant sources	Cancer model	Mechanism and effects	Reference	
DHA	Artemisia annua	Human lung cancer cell lines including NCI‐H23 and XWLC‐05	↑ROS, ↑MDA, ↓PRIM2 /SLC7A11 Axis

→Ferroptosis

	[65]	
DHA	Artemisia annua	Human acute promyelocytic leukemia cell line HL60, acute myeloid leukemia cell line KG1, and acute monocytic leukemia cell line THP‐1	↓MMP, ↑ROS, ↓NDUFS3, ↓SDHB, ↓UQCRFS1, ↓TFAM, ↓ClpP, ↑p‐AMPK, ↓mTOR/p70S6k signaling pathway

→Ferroptosis

	[66]	
DHA + CDDP	Artemisia annua	Human oral normal and cancer cell lines, including normal oral keratinocyte (NOK), SAS, and HSC3.	↓Bcl‐2, ↑Bax, ↑Caspase‐3, ↑ROS

↑Leakage of Cyt‐C and AIF from mitochondria

→Mitophagy

	[68]	
DHA	Artemisia annua	Human liver cancer cells HepG2215	↑ROS, ↑AIM2/Caspase‐1 inflammasome

→Autophagy

	[69]	
DHA	Artemisia annua	Cisplatin (DDP)‐resistant gastric cancer cell strain SGC7901/DDP	↑Caspase‐3/8/9, ↓PI3K/AKT/mTOR, ↓p‐gp, ↑Beclin1, ↑LC3‐II

→Mitophagy & Reversed the cisplatin resistance

	[70]	
DHA	Artemisia annua	Human lung cancer cell line A549	↓CIRBP, ↓PINK1/Parkin

→Reduced Mitophagy and radioresistance

	[72]	
DHA	Artemisia annua	Human ovarian epithelial cells IOSE80 and several ovarian cancer cells, SKOV3, A2780, OVCAR3 and TOV112D	↓ROS, ↓p‐ERK, ↓p‐AKT, ↓ROMO1

→Apoptosis

	[73]	
DHA	Artemisia annua	Human melanoma cell line B16F10	↓Bcl‐2, ↑Bax, ↓p‐STAT3

→Apoptosis

	[74]	
DHA‐cinnamic acid hybrids	Artemisia annua	The human breast cancer cell line MCF‐7 and MDA‐MB‐231, human non‐small‐cell lung cancer cell line A549	↓PI3K/Akt/Bad, ↑Bax, ↓Bcl‐2, ↑Caspase‐3, ↑ROS, ↓MMP

→Apoptosis

	[76]	
Mito‐DHA5	Artemisia annua	Human bladder cancer cell line T24	↓Bcl‐2, ↑Bax, ↓Cyt‐C, ↑Caspase‐3, ↓C‐PARP, ↑ROS, ↓MMP

→Apoptosis

	[77]	
DHA	Artemisia annua	Human neuroblastoma cell line SH‐SY5Y	↑PARP‐1, ↑Caspase‐3, ↑γH2AX, ↑ROS, ↓MMP, ↑DSB

→Apoptosis

	[78]	
PTL + ATO	Tanacetum parthenium	Hepatocellular carcinoma cell lines HEK293T, HepG2, MHCC 97H and Huh7	↓USP7‐HUWE1‐p53 axis, ↓PI3K/Akt/mTOR pathway↓Bcl‐2, ↑Bax, ↑ROS, ↓MMP

→Protective autophagy and apoptosis

	[88]	
PTL	Tanacetum parthenium	Human breast cancer cell line MDA‐MB231	↑p‐ERK1/2, ↑p‐JNK, ↑RIP‐1, ↓NF‐κB, ↑LC3‐II, ↑Beclin‐1, ↑ROS, ↓MMP, ↑Ca2+

→Autophagy

	[95]	
Ori	Rabdosia rubescens	Human acute myeloid leukemia cell line OCI‐AML3, Human promyelocytic leukaemia cell line HL60, Human red leucocyte leukaemia cell line HEL	↑RIPK1‐Caspase‐8‐Caspase‐3 pathway, ↑RIPK1‐RIPK3‐MLKL pathway

→Apoptosis and necroptosis

	[100]	
Ori	Rabdosia rubescens	Human esophageal squamous cancer KYSE‐30, KYSE‐150, EC9706 cell lines, and human esophageal epithelial cells (HEEC)	↓PI3K/Akt/mTOR signaling pathway, ↓Ras/Raf signaling pathway, ↑P53, ↑P21, ↑Bax, ↓Bcl‐2, ↑Caspase‐3/8/9

→Apoptosis

	[101]	
Ori + Venetoclax	Rabdosia rubescens	AML Cell Lines: THP‐1, OCI‐AML3, DNMT3A, NPM1, U‐937, MOLM13	↓AKT phosphorylation, ↑Bax, ↑Bim, ↓Mcl‐1

→Apoptosis

	[102]	
OP16 (A derivative of Oridonin)	Rabdosia rubescens	Human esophageal squamous cell carcinoma cell lines EC9706 and KYSE450	↓AKT phosphorylation, ↑Bax, ↓Bcl‐2, ↑Caspase‐3/9

→Apoptosis

	[103]	
Ori + Dox (Doxorubicin)	Rabdosia rubescens	Human osteosarcoma cell line Saos‐2	↑ROS, ↓Mcl‐1

→Apoptosis

	[110]	
Ori + Cetuximab	Rabdosia rubescens	Human laryngeal squamous cell carcinoma cell lines, HEp‐2 and Tu212	↓p‐JAK2, ↓p‐STAT3, ↓p‐PI3K, ↓p‐Akt, ↓MMP, ↑ROS

→ER stress and apoptosis

	[111]	
TPL	Tripterygium wilfordii	Human leukemia chronic myelogenous leukemia K562 and acute promyelocytic leukemia HL‐60 cells	↓NRF2, ↑ROS, ↑Lipid oxidation, ↓GPX4

→Ferroptosis

	[130]	
BA	Birch, eucalyptus and plane trees	Human ovarian cancer cell line A2780	↑Caspase‐3/8/9, ↑Bax, ↓Bcl‐2

→Apoptosis

	[145]	
BA	Birch, eucalyptus and plane trees	Human gallbladder cancer cell lines NOZ, OCUG, SGC‐996, and EHGB‐1	↓SCD1, ↑Cyt‐C, ↑Bax, ↓Bcl‐2, ↑C‐PARP, ↑Caspase‐3/9

→Apoptosis

	[146]	
OA	Widely distributed in various medicinal plants	Hepatocellular carcinoma cell line HepG2	↓NF‐κB, ↓COX‐2, ↓PCNA, ↑Bax, ↓Bcl‐2, ↑Caspase‐3

→Apoptosis and autophagy

	[165]	
OA	Widely distributed in various medicinal plants	Hepatocellular carcinoma cell line SMMC‐7721	↑Akt/mTOR signaling pathway, ↓MMP, ↓Intracellular ATP

↑Bax, ↓Bcl‐2, ↑LC3‐II, ↑Beclin‐1

→Apoptosis and autophagy

	[166]	
Abbreviations: AIF, apoptosis inducing factor; AIM2, absent in melanoma 2; AKT, AKT serine/threonine kinase; Bad, BCL2 associated agonist of cell death; Bax, BCL2 associated X, apoptosis regulator; Bcl‐2, BCL2 apoptosis regulator; Bim, Bcl‐2 interacting mediator of cell death; CIRBP, cold inducible RNA binding protein; ClpP, caseinolytic mitochondrial matrix peptidase proteolytic subunit; COX‐2, cyclooxygenase‐2; C‐PARP, CLEAVED poly ADP‐ribose polymerase; Cyt‐C, cytochrome complex; DHA, dihydroartemisinin; DSB, double strand break; GPX4, glutathione peroxidase 4; JAK2, Janus kinase 2; LC3‐II, microtubule associated protein 1 light chain 3; Mcl‐1, MCL1 apoptosis regulator, BCL2 family member; MDA, malondialdehyde; MLKL, mixed lineage kinase domain like pseudokinase; MMP, mitochondrial membrane potential; mTOR, mechanistic target of rapamycin kinase; NDUFS3, NADH, ubiquinone oxidoreductase core subunit S3; NF‐κB, nuclear factor kappa b subunit 1; NRF2, NF‐E2‐related factor 2; P53, tumor protein P53; p70S6k, p70 ribosomal protein S6 kinase; p‐AKT, phosphorylation‐AKT serine/threonine kinase; p‐AMPK, phosphorylation‐adenosine 5′‐monophosphate (AMP)‐activated protein kinase; Parkin, parkin RBR E3 ubiquitin protein ligase; PARP‐1, poly ADP‐ribose polymerase‐1; PCNA, proliferating cell nuclear antigen; p‐ERK, phosphorylation‐extracellular‐regulated protein kinases; p‐ERK1/2 extracellular‐regulated kinase 1/2; p‐gp, P‐glycoprotein; PI3K, phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit delta; PINK1, PTEN induced kinase 1; p‐JNK, phosphorylation‐mitogen‐activated protein kinase 8; PRIM2, DNA primase subunit 2; p‐STAT3, phosphorylation‐signal transducer and activator of transcription 3; Raf, Raf proto‐oncogene, serine/threonine kinase; Ras, Rat sarcoma; RIP‐1, receptor‐interacting protein‐1; RIPK, receptor‐interacting serine/threonine kinase; ROMO1, reactive oxygen species modulator 1; ROS, reactive oxygen species; SCD, Stearoyl‐CoA Desaturase; SDHB, succinate dehydrogenase complex iron sulfur subunit B; SLC7A11, solute carrier family 7 member 11; TFAM, transcription factor A, mitochondrial; UQCRFS1, ubiquinol‐cytochrome C reductase, rieske iron sulfur polypeptide 1; γH2AX, γH2A.X variant histone.

TABLE 2 In vivo studies of terpenoids as inducers of mitochondrial death in tumor cells Table.

Terpenoids	Plant sources	Cancer model	Mechanism and effects	Reference	
DHA + DDP	Artemisia annua	BALB/c mice were subcutaneously injected with the pancreatic cancer cell line PANC1 cells	↓ATP, ↑ROS, ↓GPX4

→Ferroptosis

	[67]	
DHA + CDDP	Artemisia annua	The OSCC tumor‐xenograft mice	↑LC3‐II, ↑P62

→Mitophagy

	[68]	
DHA	Artemisia annua	Melanoma‐bearing BALB/c mice	↑IFN‐γ, ↓IL‐10, ↓p‐STAT3

→Apoptosis

	[74]	
DHA + DTX	Artemisia annua	Mice with metastatic breast cancer in situ derived from 4T1 cells	↑ROS, ↓MMP, ↑P53, ↑Cyt C release into the cytoplasm, ↑Caspase‐3

→Apoptosis

	[75]	
Ori	Rabdosia rubescens	Esophageal cancer xenograft in mice	↓PI3K/Akt/mTOR signaling pathway, ↓Ras/Raf signaling pathway, ↑P53, ↑P21, ↑Bax, ↓Bcl‐2, ↑Caspase‐3/8/9

→Apoptosis

	[101]	
Ori + Venetoclax	Rabdosia rubescens	AML mouse model	↓The growth of AML xenograft tumors in mice

↑The survival time of tumor‐bearing mice

	[102]	
TPL + JQ1 (A bromodomain and extra‐terminal domain inhibitor)	Tripterygium wilfordii	BALB/c mice were subcutaneously injected with the AML cell line MOLM‐13 cells

	↑ROS, ↓c‐Myc, ↓Tumor weight and volume	[127]	
CK21 (A derivative of Triptolide)	Tripterygium wilfordii	BALB/c mice were subcutaneously injected with the pancreatic cancer cell line PANC1 cells and AsPC‐1 cells	↓NF‐κB, ↑ROS

↓The growth of AML xenograft tumors in mice

↑The survival time of tumor‐bearing mice

→Apoptosis

	[128]	
B5G1 (A betulinic acid analog)	Birch, eucalyptus, and plane trees	BALB/c mice were subcutaneously injected with the HepG2/ADM cells	↑PINK1, ↑p‐Parkin, ↓The growth of HepG2/ADM xenografts

→Apoptosis and mitochondrial autophagy

	[151]	
OA	Widely distributed in various medicinal plants	DMBA‐induced hepatocellular carcinoma in situ model mice	↓NF‐κB, ↓Bcl‐2, ↑Caspase‐3, ↑Beclin‐1

→Apoptosis and autophagy

	[165]	
Abbreviations: ATP, adenosine 5′‐triphosphate; AKT, AKT serine/threonine kinase; Bax, BCL2 associated X, apoptosis regulator; Bcl‐2, BCL2 apoptosis regulator; Cyt‐C, cytochrome Complex; GPX4, glutathione peroxidase 4; LC3‐II, microtubule associated protein 1 light chain 3; MMP, mitochondrial membrane potential; mTOR, mechanistic target of rapamycin kinase; MYC, MYC proto‐oncogene; NF‐κB, nuclear factor kappa b subunit 1; P21, CKI; P53, tumor protein P53; P62, sequestosome 1; PI3K, phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit delta; PINK1, PTEN induced kinase 1; p‐STAT3, phosphorylation‐signal transducer and activator of transcription 3; Raf, Raf proto‐oncogene, serine/threonine kinase; Ras, Rat sarcoma; ROS, reactive oxygen species.

6 Conclusion

Mitochondria are double‐membrane‐bound organelles that provide energy for cellular metabolism and play a key role in cell death. Growing evidence has indicated that mitochondrion‐dependent cell death plays a crucial role in tumors. Therefore, targeting mitochondria and inducing mitochondrial death in tumor cells is a promising therapeutic approach. Terpenoids, the most extensive category of natural compounds, have demonstrated the capability to induce mitochondrial apoptosis in malignant cells. However, the precise mechanism by which terpenoids cause mitochondrial cell death remains unclear. This review emphasizes the significance of selecting terpenoids in triggering mitochondrial death in cancer cells and their potential as therapeutic agents for cancer.

The results of this review indicated that terpenoids trigger mitochondrial cell death in cancer cells through several mechanisms, including autophagy, ferroptosis, pyroptosis, necroptotic cell death, apoptosis, and necrosis mediated by mitochondrial permeability transition. It is intricately associated with multiple signaling pathways, including PI3K/AKT/mTOR, RIPK1‐RIPK3‐MLKL, MAPK/ERK/JNK, Ras/Raf, SIRT‐1/CAV‐1 axis, and NF‐κB (Figure 2). Interestingly, some studies have demonstrated that terpenoid‐induced mitochondrial apoptosis coincides with protective autophagy initiation facilitated by PINK1/Parkin or PI3K/Akt/mTOR. Consequently, elucidating the roles of signaling pathways involved in tumorigenesis may reveal new candidates for cancer treatment.

FIGURE 2 The effect of terpenoids on the mitochondrion‐dependent cell death signaling pathways. The terpenoids alone (green oval) exhibit the complex manner in which these secondary metabolites trigger the death of cells that rely on mitochondria via complicated signaling pathways like PI3K/AKT/mTOR, RIPK1‐RIPK3‐MLKL, MAPK/ERK/JNK, Ras/Raf, SIRT‐1/CAV‐1 axis, and NF‐κB. AKT, serine/threonine kinase; AMPK, AMP‐activated kinase; Bax, BCL2 associated X, apoptosis regulator; Bcl‐2, BCL2 apoptosis regulator; Cas‐3, Caspase‐3; Cas‐8, Caspase‐8; Cas‐9, Caspase‐9; c‐KIT, mast/stem cell growth factor receptor Kit; Cyt‐C, cytochrome complex; ER, sarcoplasmic/endoplasmic; GPX4, glutathione peroxidase 4; HUWE1, HECT, UBA, and WWE domain containing E3 ubiquitin protein ligase 1; JNK, c‐jun N‐terminal kinase; MAPK, mitogen‐activated protein kinase; Mcl‐1, MCL1 apoptosis regulator, BCL2 family member; mTOR, mechanistic target of rapamycin kinase; NF‐κB, nuclear factor kappa b subunit 1; NRF2, nuclear respiratory factors 2; P53, tumor protein P53; PARKIN, parkin RBR E3 ubiquitin protein; PARP, poly ADP‐ribose polymerase; PI3K, phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit delta; PINK1, PTEN induced kinase 1; ROS, reactive oxygen species; SLC25A1, solute carrier family 25 member 1; SLC7A11, solute carrier family 7 member 11; Sirt6, Sirtuin 6; STAT3, signal transducer and activator of transcription 3; USP7, ubiquitin specific peptidase 7; ΔΨm, mitochondrial membrane potential.

Another focus of the present review was the interplay between autophagy and apoptosis. Despite their differences in molecular biological pathways, they do affect each other in some cases. Autophagy has been shown to inhibit apoptosis, indicating that apoptosis becomes more probable when autophagy is suppressed. However, autophagy may facilitate apoptosis induction in certain instances. Deciphering the intricate association between autophagy and apoptosis provides new possibilities for cancer treatment. Protective autophagy suppression improves the cancer cells' sensitivity to apoptosis, whereas partial autophagy activation accelerates the onset of apoptosis.

Notably, structural modification, nanodelivery system adoption, and tandem administration of chemotherapeutic drugs improved the efficacy and bioavailability of terpenoids and mitigated chemoresistance. This reminds us of the feasibility of looking for anticancer drug leads among natural compounds.

Currently, research on the pharmacological actions of terpenoids and their derivatives primarily depends on in vivo and in vitro models for empirical data and theories regarding mechanisms, laying the foundation for clinical application. Unfortunately, the following issues remain unresolved: (a) terpenoid research remains in the preclinical phase, thereby lacking clinical trial data to support the studies; (b) the optimal dosage of terpenoids and their potential toxic side effects remain unclear; and (c) additional studies to elucidate the effects of terpenoids on mitochondrial cell death and reveal the complexity of the many signaling pathways involved are lacking. Several advanced techniques, such as bioinformatics, histology, and artificial intelligence, can be used to elucidate the effects of terpenoids on mitochondrial cell death and reveal the complexity of the signaling pathways involved before developing better anticancer treatments. In conclusion, terpenoids exhibit a great antitumor potential.

Author Contributions

Jianxin Guo: writing – review and editing, writing – original draft, visualization. Ming Huang: writing – original draft, writing – review and editing. Shuang Hou: writing – review and editing, writing – original draft, data curation. Jianfeng Yuan: writing – review and editing, writing – original draft, data curation. Xiaoyue Chang: writing – review and editing. Shuang Gao: writing – review and editing. Zhenhan Zhang: writing – review and editing. Zhongbing Wu: funding acquisition, writing – review and editing, project administration, visualization. Jing Li: funding acquisition, writing – review and editing, project administration, conceptualization, formal analysis, supervision.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

The authors thank Figdraw for help with Figures 1 and 2.

Data Availability Statement

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
==== Refs
References

1 R. L. Siegel , A. N. Giaquinto , and A. Jemal , “Cancer Statistics, 2024,” CA: A Cancer Journal for Clinicians 74 , no. 1 (2024): 12–49.38230766
2 W. Cao , H. D. Chen , Y. W. Yu , N. Li , and W. Q. Chen , “Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020,” Chinese Medical Journal 134 , no. 7 (2021): 783–791.33734139
3 R. L. Siegel , K. D. Miller , H. E. Fuchs , and A. Jemal , “Cancer Statistics, 2022,” CA: A Cancer Journal for Clinicians 72 , no. 1 (2022): 7–33.35020204
4 R. L. Siegel , K. D. Miller , N. S. Wagle , and A. Jemal , “Cancer Statistics, 2023,” CA: A Cancer Journal for Clinicians 73 , no. 1 (2023): 17–48.36633525
5 L. Sainero‐Alcolado , J. Liaño‐Pons , M. V. Ruiz‐Pérez , and M. Arsenian‐Henriksson , “Targeting Mitochondrial Metabolism for Precision Medicine in Cancer,” Cell Death and Differentiation 29 , no. 7 (2022): 1304–1317.35831624
6 P. K. Kopinski , L. N. Singh , S. Zhang , M. T. Lott , and D. C. Wallace , “Mitochondrial DNA Variation and Cancer,” Nature Reviews Cancer 21 , no. 7 (2021): 431–445.34045735
7 A. M. Van Der Bliek , M. M. Sedensky , and P. G. Morgan , “Cell Biology of the Mitochondrion,” Genetics 207 , no. 3 (2017): 843–871.29097398
8 D. C. Wallace , “A Mitochondrial Paradigm of Metabolic and Degenerative Diseases, Aging, and Cancer: A Dawn for Evolutionary Medicine,” Annual Review of Genetics 39 (2005): 359–407.
9 F. J. Bock and S. W. G. Tait , “Mitochondria as Multifaceted Regulators of Cell Death,” Nature Reviews. Molecular Cell Biology 21 , no. 2 (2020): 85–100.31636403
10 T. T. Nguyen , S. Wei , T. H. Nguyen , et al., “Mitochondria‐Associated Programmed Cell Death as a Therapeutic Target for Age‐Related Disease,” Experimental & Molecular Medicine 55 , no. 8 (2023): 1595–1619.37612409
11 P. Singh and B. Lim , “Targeting Apoptosis in Cancer,” Current Oncology Reports 24 , no. 3 (2022): 273–284.35113355
12 C. Tian , Y. Liu , Z. Li , P. Zhu , and M. Zhao , “Mitochondria Related Cell Death Modalities and Disease,” Frontiers in Cell and Development Biology 10 (2022): 832356.
13 H. Wang , C. Liu , Y. Zhao , and G. Gao , “Mitochondria Regulation in Ferroptosis,” European Journal of Cell Biology 99 , no. 1 (2020): 151058.31810634
14 H. L. Glover , A. Schreiner , G. Dewson , and S. W. G. Tait , “Mitochondria and Cell Death,” Nature Cell Biology (2024), 10.1038/s41556-024-01429-4.
15 M. Yang , X. Wei , X. Yi , and D. S. Jiang , “Mitophagy‐Related Regulated Cell Death: Molecular Mechanisms and Disease Implications,” Cell Death & Disease 15 , no. 7 (2024): 505.39013891
16 T. Behl , R. Makkar , M. K. Anwer , et al., “Mitochondrial Dysfunction: A Cellular and Molecular hub in Pathology of Metabolic Diseases and Infection,” Journal of Clinical Medicine 12 , no. 8 (2023): 2882.37109219
17 H. El‐Nashar , M. A. Al‐Azzawi , H. H. Al‐Kazzaz , et al., “HPLC‐ESI/MS‐MS Metabolic Profiling of White Pitaya Fruit and Cytotoxic Potential Against Cervical Cancer: Comparative Studies, Synergistic Effects, and Molecular Mechanistic Approaches,” Journal of Pharmaceutical and Biomedical Analysis 244 (2024): 116121.38581932
18 M. Ashrafizadeh , A. R. Aref , G. Sethi , Y. N. Ertas , and L. Wang , “Natural Product/Diet‐Based Regulation of Macrophage Polarization: Implications in Treatment of Inflammatory‐Related Diseases and Cancer,” Journal of Nutritional Biochemistry 130 (2024): 109647.38604457
19 H. El‐Nashar , S. H. Aly , A. Ahmadi , and M. El‐Shazly , “The Impact of Polyphenolics in the Management of Breast Cancer: Mechanistic Aspects and Recent Patents,” Recent Patents on Anti‐Cancer Drug Discovery 17 , no. 4 (2022): 358–379.34961465
20 T. Andreani , R. Cheng , K. Elbadri , et al., “Natural Compounds‐Based Nanomedicines for Cancer Treatment: Future Directions and Challenges,” Drug Delivery and Translational Research (2024), 10.1007/s13346-024-01649-z.
21 C. El‐Baba , A. Baassiri , G. Kiriako , et al., “Terpenoids' Anti‐Cancer Effects: Focus on Autophagy,” Apoptosis 26 , no. 9–10 (2021): 491–511.34269920
22 F. Fontana , M. Raimondi , M. Marzagalli , A. di Domizio , and P. Limonta , “The Emerging Role of Paraptosis in Tumor Cell Biology: Perspectives for Cancer Prevention and Therapy With Natural Compounds,” Biochimica Et Biophysica Acta. Reviews on Cancer 1873 , no. 2 (2020): 188338.31904399
23 F. Wei , Q. Nian , M. Zhao , et al., “Natural Products and Mitochondrial Allies in Colorectal Cancer Therapy,” Biomedicine & Pharmacotherapy 167 (2023): 115473.37713992
24 Y. Yang , P. Y. He , Y. Zhang , and N. Li , “Natural Products Targeting the Mitochondria in Cancers,” Molecules 26 , no. 1 (2020): 92.33379233
25 S. H. Aly , A. M. M. Elbadry , A. S. Doghish , and H. A. S. el‐Nashar , “Unveiling the Pharmacological Potential of Plant Triterpenoids in Breast Cancer Management: An Updated Review,” Naunyn‐Schmiedeberg's Archives of Pharmacology 397 , no. 8 (2024): 5571–5596.38563878
26 J. Gershenzon and N. Dudareva , “The Function of Terpene Natural Products in the Natural World,” Nature Chemical Biology 3 , no. 7 (2007): 408–414.17576428
27 T. Rabi and A. Bishayee , “Terpenoids and Breast Cancer Chemoprevention,” Breast Cancer Research and Treatment 115 , no. 2 (2009): 223–239.18636327
28 S. T. Withers and J. D. Keasling , “Biosynthesis and Engineering of Isoprenoid Small Molecules,” Applied Microbiology and Biotechnology 73 , no. 5 (2007): 980–990.17115212
29 M. Huang , J. J. Lu , M. Q. Huang , J. L. Bao , X. P. Chen , and Y. T. Wang , “Terpenoids: Natural Products for Cancer Therapy,” Expert Opinion on Investigational Drugs 21 , no. 12 (2012): 1801–1818.23092199
30 H. Y. Chen , J. Y. Lei , S. L. Li , et al., “Progress in Biological Activities and Biosynthesis of Edible Fungi Terpenoids,” Critical Reviews in Food Science and Nutrition 63 , no. 25 (2023): 7288–7310.35238261
31 B. Chopra , A. K. Dhingra , K. L. Dhar , and K. Nepali , “Emerging Role of Terpenoids for the Treatment of Cancer: A Review,” Mini Reviews in Medicinal Chemistry 21 , no. 16 (2021): 2300–2336.33438537
32 H. Luo , C. T. Vong , H. Chen , et al., “Naturally Occurring Anti‐Cancer Compounds: Shining From Chinese Herbal Medicine,” Chinese Medicine 14 (2019): 48.31719837
33 T. Zeng , Z. Liu , H. Liu , et al., “Exploring Chemical and Biological Space of Terpenoids,” Journal of Chemical Information and Modeling 59 , no. 9 (2019): 3667–3678.31403297
34 J. Zi , S. Mafu , and R. J. Peters , “To Gibberellins and Beyond! Surveying the Evolution of (di)terpenoid Metabolism,” Annual Review of Plant Biology 65 (2014): 259–286.
35 E. Pichersky and R. A. Raguso , “Why Do Plants Produce so Many Terpenoid Compounds?” New Phytologist 220 , no. 3 (2018): 692–702.27604856
36 F. Chen , D. Tholl , J. Bohlmann , and E. Pichersky , “The Family of Terpene Synthases in Plants: A Mid‐Size Family of Genes for Specialized Metabolism That Is Highly Diversified Throughout the Kingdom,” Plant Journal 66 , no. 1 (2011): 212–229.
37 M. Tian , B. Jin , L. Chen , et al., “Functional Diversity of Diterpene Synthases in Aconitum Plants,” Plant Physiology and Biochemistry 202 (2023): 107968.37619270
38 Q. Jia , R. Brown , T. G. Köllner , et al., “Origin and Early Evolution of the Plant Terpene Synthase Family,” Proceedings of the National Academy of Sciences of the United States of America 119 , no. 15 (2022): e2100361119.35394876
39 Y. Hoshino and L. Villanueva , “Four Billion Years of Microbial Terpenome Evolution,” FEMS Microbiology Reviews 47 , no. 2 (2023): fuad008.36941124
40 D. Boncan , S. S. K. Tsang , C. Li , et al., “Terpenes and Terpenoids in Plants: Interactions With Environment and Insects,” International Journal of Molecular Sciences 21 , no. 19 (2020): 7382.33036280
41 M. E. Bergman , B. Davis , and M. A. Phillips , “Medically Useful Plant Terpenoids: Biosynthesis, Occurrence, and Mechanism of Action,” Molecules 24 , no. 21 (2019): 3961.31683764
42 M. Avalos , P. Garbeva , L. Vader , G. P. van Wezel , J. S. Dickschat , and D. Ulanova , “Biosynthesis, Evolution and Ecology of Microbial Terpenoids,” Natural Product Reports 39 , no. 2 (2022): 249–272.34612321
43 M. Jiang , Z. Wu , H. Guo , L. Liu , and S. Chen , “A Review of Terpenes From Marine‐Derived Fungi: 2015‐2019,” Marine Drugs 18 , no. 6 (2020): 321.32570903
44 C. Avila , “Terpenoids in Marine Heterobranch Molluscs,” Marine Drugs 18 , no. 3 (2020): 162.32183298
45 S. Y. Ng , C. S. Phan , T. Ishii , T. Kamada , T. Hamada , and C. S. Vairappan , “Terpenoids From Marine Soft Coral of the Genus Xenia in 1977 to 2019,” Molecules 25 , no. 22 (2020): 386.31963466
46 L. Núñez‐Pons , A. Shilling , C. Verde , B. J. Baker , and D. Giordano , “Marine Terpenoids From Polar Latitudes and Their Potential Applications in Biotechnology,” Marine Drugs 18 , no. 8 (2020): 401.32751369
47 L. Chen , Y. Pang , Y. Luo , X. Cheng , B. Lv , and C. Li , “Separation and Purification of Plant Terpenoids From Biotransformation,” Engineering in Life Sciences 21 , no. 11 (2021): 724–738.34764825
48 S. Moser and H. Pichler , “Identifying and Engineering the Ideal Microbial Terpenoid Production Host,” Applied Microbiology and Biotechnology 103 , no. 14 (2019): 5501–5516.31129740
49 X. W. Yin , X. X. Bian , Y. F. Chen , et al., “Structure‐Diversified Terpenoids From Salvia Prattii and Their Protective Activity Against Alcoholic Liver Diseases,” Phytochemistry 214 (2023): 113819.37572737
50 K. Wang , J. Liu , J. Huang , et al., “Discovery of Uncommon Terpenoids From the South China sea Soft Coral Sinularia Scabra,” Phytochemistry 209 (2023): 113616.36828101
51 K. Kuck , A. Unterholzner , B. Lipowicz , et al., “Terpenoids From Myrrh and Their Cytotoxic Activity Against HeLa Cells,” Molecules 28 , no. 4 (2023): 1637.36838624
52 W. S. Kim , Z. A. Shalit , S. M. Nguyen , et al., “A Synthesis Strategy for Tetracyclic Terpenoids Leads to Agonists of ERβ,” Nature Communications 10 , no. 1 (2019): 2448.
53 X. R. Peng , S. B. Unsicker , J. Gershenzon , and M. H. Qiu , “Structural Diversity, Hypothetical Biosynthesis, Chemical Synthesis, and Biological Activity of Ganoderma Meroterpenoids,” Natural Product Reports 40 , no. 8 (2023): 1354–1392.37051770
54 J. Couillaud , L. Leydet , K. Duquesne , and G. Iacazio , “The Terpene Mini‐Path, a New Promising Alternative for Terpenoids bio‐Production,” Genes (Basel) 12 , no. 12 (2021): 1974.34946923
55 P. C. Lin and H. B. Pakrasi , “Engineering Cyanobacteria for Production of Terpenoids,” Planta 249 , no. 1 (2019): 145–154.30465115
56 O. Klaus , F. Hilgers , A. Nakielski , et al., “Engineering Phototrophic Bacteria for the Production of Terpenoids,” Current Opinion in Biotechnology 77 (2022): 102764.35932511
57 J. A. Bureau , M. E. Oliva , Y. Dong , and C. Ignea , “Engineering Yeast for the Production of Plant Terpenoids Using Synthetic Biology Approaches,” Natural Product Reports 40 , no. 12 (2023): 1822–1848.37523210
58 T. L. Zhang , H. W. Yu , and L. D. Ye , “Metabolic Engineering of Yarrowia Lipolytica for Terpenoid Production: Tools and Strategies,” ACS Synthetic Biology 12 , no. 3 (2023): 639–656.36867718
59 J. Gutman , S. Kovacs , G. Dorsey , A. Stergachis , and F. O. ter Kuile , “Safety, Tolerability, and Efficacy of Repeated Doses of Dihydroartemisinin‐Piperaquine for Prevention and Treatment of Malaria: A Systematic Review and Meta‐Analysis,” Lancet Infectious Diseases 17 , no. 2 (2017): 184–193.27865890
60 N. Ma , Z. Zhang , F. Liao , T. Jiang , and Y. Tu , “The Birth of Artemisinin,” Pharmacology & Therapeutics 216 (2020): 107658.32777330
61 Y. Tu , “The Discovery of Artemisinin (Qinghaosu) and Gifts From Chinese Medicine,” Nature Medicine 17 , no. 10 (2011): 1217–1220.
62 T. Efferth , “From Ancient Herb to Modern Drug: Artemisia Annua and Artemisinin for Cancer Therapy,” Seminars in Cancer Biology 46 (2017): 65–83.28254675
63 X. Dai , X. Zhang , W. Chen , et al., “Dihydroartemisinin: A Potential Natural Anticancer Drug,” International Journal of Biological Sciences 17 , no. 2 (2021): 603–622.33613116
64 B. Abuaku , P. Boateng , N. Y. Peprah , et al., “Therapeutic Efficacy of Dihydroartemisinin‐Piperaquine Combination for the Treatment of Uncomplicated Malaria in Ghana,” Frontiers in Cellular and Infection Microbiology 12 (2022): 1058660.36683700
65 B. Yuan , F. Liao , Z. Z. Shi , et al., “Dihydroartemisinin Inhibits the Proliferation, Colony Formation and Induces Ferroptosis of Lung Cancer Cells by Inhibiting PRIM2/SLC7A11 Axis,” Oncotargets and Therapy 13 (2020): 10829–10840.33149601
66 J. Du , T. Wang , Y. Li , et al., “DHA Inhibits Proliferation and Induces Ferroptosis of Leukemia Cells Through Autophagy Dependent Degradation of Ferritin,” Free Radical Biology & Medicine 131 (2019): 356–369.30557609
67 J. Du , X. Wang , Y. Li , et al., “DHA Exhibits Synergistic Therapeutic Efficacy With Cisplatin to Induce Ferroptosis in Pancreatic Ductal Adenocarcinoma via Modulation of Iron Metabolism,” Cell Death & Disease 12 , no. 7 (2021): 705.34262021
68 S. Shi , H. Luo , Y. Ji , et al., “Repurposing Dihydroartemisinin to Combat Oral Squamous Cell Carcinoma, Associated With Mitochondrial Dysfunction and Oxidative Stress,” Oxidative Medicine and Cellular Longevity 25 (2023): 9595201.
69 X. Shi , L. Wang , L. Ren , et al., “Dihydroartemisinin, an Antimalarial Drug, Induces Absent in Melanoma 2 Inflammasome Activation and Autophagy in Human Hepatocellular Carcinoma HepG2215 Cells,” Phytotherapy Research 33 , no. 5 (2019): 1413–1425.30873702
70 S. Zhang , R. Feng , F. Yuan , et al., “The Therapeutic Effects of Dihydroartemisinin on Cisplatin‐Resistant Gastric Cancer Cells,” Current Pharmaceutical Biotechnology 23 , no. 2 (2022): 276–286.33596797
71 F. Antunes , A. G. Erustes , A. J. Costa , et al., “Autophagy and Intermittent Fasting: The Connection for Cancer Therapy?” Clinics (São Paulo, Brazil) 73 , no. suppl 1 (2018): e814s.30540126
72 S. Wu , Z. Li , H. Li , and K. Liao , “Dihydroartemisinin Reduces Irradiation‐Induced Mitophagy and Radioresistance in Lung Cancer A549 Cells via CIRBP Inhibition,” Life 12 , no. 8 (2022): 1129.36013308
73 Y. Yan , X. Yang , N. Han , et al., “Metal‐Organic Framework‐Encapsulated Dihydroartemisinin Nanoparticles Induces Apoptotic Cell Death in Ovarian Cancer by Blocking ROMO1‐Mediated ROS Production,” Journal of Nanobiotechnology 21 , no. 1 (2023): 204.37386404
74 R. Yu , L. Jin , F. Li , et al., “Dihydroartemisinin Inhibits Melanoma by Regulating CTL/Treg Anti‐Tumor Immunity and STAT3‐Mediated Apoptosis via IL‐10 Dependent Manner,” Journal of Dermatological Science 99 , no. 3 (2020): 193–202.32859456
75 J. Tao , L. Diao , F. Chen , et al., “pH‐Sensitive Nanoparticles Codelivering Docetaxel and Dihydroartemisinin Effectively Treat Breast Cancer by Enhancing Reactive Oxidative Species‐Mediated Mitochondrial Apoptosis,” Molecular Pharmaceutics 18 , no. 1 (2021): 74–86.33084332
76 Y. Hu , Y. Wang , N. Li , L. Chen , and J. Sun , “Discovery of Novel Dihydroartemisinin‐Cinnamic Hybrids Inducing Lung Cancer Cells Apoptosis via Inhibition of Akt/Bad Signal Pathway,” Bioorganic Chemistry 111 (2021): 104903.33894433
77 L. Xiao , C. Xu , P. Lin , L. Mu , and X. Yang , “Novel Dihydroartemisinin Derivative Mito‐DHA(5) Induces Apoptosis Associated With Mitochondrial Pathway in Bladder Cancer Cells,” BMC Pharmacology and Toxicology 23 , no. 1 (2022): 10.35057867
78 D. L. Xu , K. Fan , H. Zhang , et al., “Anti‐Proliferation and Apoptosis‐Inducing Effects of Dihydroartemisinin on SH‐SY5Y Cells and Metabolomic Analysis,” Translational Pediatrics 11 , no. 8 (2022): 1346–1361.36072536
79 S. Krishna , S. Ganapathi , I. C. Ster , et al., “A Randomised, Double Blind, Placebo‐Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer,” eBioMedicine 2 , no. 1 (2015): 82–90.26137537
80 K. H. Wong , D. Yang , S. Chen , C. He , and M. Chen , “Development of Nanoscale Drug Delivery Systems of Dihydroartemisinin for Cancer Therapy: A Review,” Asian Journal of Pharmaceutical Sciences 17 , no. 4 (2022): 475–490.36105316
81 R. Kumar , M. Singh , J. Meena , et al., “Hyaluronic Acid ‐ Dihydroartemisinin Conjugate: Synthesis, Characterization and in Vitro Evaluation in Lung Cancer Cells,” International Journal of Biological Macromolecules 133 (2019): 495–502.31004634
82 J. J. Liu , W. Tang , M. Fu , et al., “Development of R(8) Modified Epirubicin‐Dihydroartemisinin Liposomes for Treatment of Non‐small‐Cell Lung Cancer,” Artificial Cells, Nanomedicine, and Biotechnology 47 , no. 1 (2019): 1947–1960.31079495
83 D. Huang , D. Xu , W. Chen , et al., “Fe‐MnO(2) Nanosheets Loading Dihydroartemisinin for Ferroptosis and Immunotherapy,” Biomedicine & Pharmacotherapy 161 (2023): 114431.36827713
84 L. Liu , Y. Wei , S. Zhai , Q. Chen , and D. Xing , “Dihydroartemisinin and Transferrin Dual‐Dressed Nano‐Graphene Oxide for a pH‐Triggered Chemotherapy,” Biomaterials 62 (2015): 35–46.26022978
85 A. Ghantous , A. Sinjab , Z. Herceg , and N. Darwiche , “Parthenolide: From Plant Shoots to Cancer Roots,” Drug Discovery Today 18 , no. 17–18 (2013): 894–905.23688583
86 R. R. A. Freund , P. Gobrecht , D. Fischer , and H. D. Arndt , “Advances in Chemistry and Bioactivity of Parthenolide,” Natural Product Reports 37 , no. 4 (2020): 541–565.31763637
87 Z. Zhang , Y. Qiao , Q. Sun , L. Peng , and L. Sun , “A Novel SLC25A1 Inhibitor, Parthenolide, Suppresses the Growth and Stemness of Liver Cancer Stem Cells With Metabolic Vulnerability,” Cell Death Discovery 9 , no. 1 (2023): 350.37741815
88 J. Yi , X. Gong , X. Y. Yin , et al., “Parthenolide and Arsenic Trioxide Co‐Trigger Autophagy‐Accompanied Apoptosis in Hepatocellular Carcinoma Cells,” Frontiers in Oncology 12 (2022): 988528.36353537
89 S. Wang , K. Wang , C. Zhang , et al., “Overaccumulation of p53‐Mediated Autophagy Protects Against Betulinic Acid‐Induced Apoptotic Cell Death in Colorectal Cancer Cells,” Cell Death & Disease 8 , no. 10 (2017): e3087.28981110
90 L. Galluzzi , O. Kepp , and G. Kroemer , “Mitochondria: Master Regulators of Danger Signalling,” Nature Reviews. Molecular Cell Biology 13 , no. 12 (2012): 780–788.23175281
91 M. M. Young , Y. Takahashi , O. Khan , et al., “Autophagosomal Membrane Serves as Platform for Intracellular Death‐Inducing Signaling Complex (iDISC)‐mediated Caspase‐8 Activation and Apoptosis,” Journal of Biological Chemistry 287 , no. 15 (2012): 12455–12468.22362782
92 I. P. Nezis , B. V. Shravage , A. P. Sagona , et al., “Autophagic Degradation of dBruce Controls DNA Fragmentation in Nurse Cells During Late Drosophila melanogaster Oogenesis,” Journal of Cell Biology 190 , no. 4 (2010): 523–531.20713604
93 F. V. Lobianco , K. J. Krager , E. Johnson , et al., “Parthenolide Induces Rapid Thiol Oxidation That Leads to Ferroptosis in Hepatocellular Carcinoma Cells,” Frontiers in Toxicology 4 (2022): 936149.36591540
94 J. Jorge , J. Neves , R. Alves , C. Geraldes , A. C. Gonçalves , and A. B. Sarmento‐Ribeiro , “Parthenolide Induces ROS‐Mediated Apoptosis in Lymphoid Malignancies,” International Journal of Molecular Sciences 24 , no. 11 (2023): 9167.37298119
95 A. D'anneo , D. Carlisi , M. Lauricella , et al., “Parthenolide Generates Reactive Oxygen Species and Autophagy in MDA‐MB231 Cells. A Soluble Parthenolide Analogue Inhibits Tumour Growth and Metastasis in a Xenograft Model of Breast Cancer,” Cell Death & Disease 4 , no. 10 (2013): e891.24176849
96 D. Capece , D. Verzella , B. Di Francesco , et al., “NF‐κB and Mitochondria Cross Paths in Cancer: Mitochondrial Metabolism and Beyond,” Seminars in Cell & Developmental Biology 98 (2020): 118–128.31132468
97 L. Zhao , J. Y. Lee , and D. H. Hwang , “Inhibition of Pattern Recognition Receptor‐Mediated Inflammation by Bioactive Phytochemicals,” Nutrition Reviews 69 , no. 6 (2011): 310–320.21631512
98 N. R. Penthala , M. Balasubramaniam , S. S. Dachavaram , et al., “Antitumor Properties of Novel Sesquiterpene Lactone Analogs as NFκB Inhibitors That Bind to the IKKβ Ubiquitin‐Like Domain (ULD),” European Journal of Medicinal Chemistry 224 (2021): 113675.34229108
99 X. Li , C. T. Zhang , W. Ma , X. Xie , and Q. Huang , “Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity,” Frontiers in Pharmacology 12 (2021): 645824.34295243
100 M. Liao , Q. Dong , R. Chen , et al., “Oridonin Inhibits DNMT3A R882 Mutation‐Driven Clonal Hematopoiesis and Leukemia by Inducing Apoptosis and Necroptosis,” Cell Death Discovery 7 , no. 1 (2021): 297.34663800
101 J. H. Jiang , J. Pi , H. Jin , and J. Y. Cai , “Oridonin‐Induced Mitochondria‐Dependent Apoptosis in Esophageal Cancer Cells by Inhibiting PI3K/AKT/mTOR and Ras/Raf Pathways,” Journal of Cellular Biochemistry 120 , no. 3 (2019): 3736–3746.30229997
102 L. Chen , D. Li , X. Guo , C. Cheng , and X. Wei , “Oridonin Synergistically Enhances the pro‐Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling,” Frontiers in Bioscience‐Landmark 28 , no. 9 (2023): 195.
103 G. Hou , A. Jia , L. Yang , et al., “OP16 Induces Deadly Autophagy and Apoptosis of Cells by Inhibiting Akt in Esophageal Squamous Cell Carcinoma,” Molecular and Cellular Biochemistry 472 , no. 1–2 (2020): 219–230.32671513
104 M. Shariati and F. Meric‐Bernstam , “Targeting AKT for Cancer Therapy,” Expert Opinion on Investigational Drugs 28 , no. 11 (2019): 977–988.31594388
105 Y. Liu , Z. Song , Y. Liu , et al., “Identification of Ferroptosis as a Novel Mechanism for Antitumor Activity of Natural Product Derivative a2 in Gastric Cancer,” Acta Pharmaceutica Sinica B 11 , no. 6 (2021): 1513–1525.34221865
106 H. Li , B. Sun , M. Wang , et al., “Bioactive Enmein‐Type 6,7‐Seco‐Ent‐Kaurane Diterpenoids: Natural Products, Synthetic Derivatives and Apoptosis Related Mechanism,” Archives of Pharmacal Research 41 , no. 11 (2018): 1051–1061.30242610
107 X. Ni , C. He , Y. Jia , et al., “Spirolactone‐Type and Enmein‐Type Derivatives as Potential Anti‐Cancer Agents Derived From Oridonin,” Bioorganic & Medicinal Chemistry 72 (2022): 116977.36037626
108 D. Luo , Y. Yi , K. Peng , et al., “Oridonin Derivatives as Potential Anticancer Drug Candidates Triggering Apoptosis Through Mitochondrial Pathway in the Liver Cancer Cells,” European Journal of Medicinal Chemistry 178 (2019): 365–379.31200238
109 W. Zhang , Y. Lu , T. Zhen , et al., “Homoharringtonine Synergy With Oridonin in Treatment of t(8; 21) Acute Myeloid Leukemia,” Frontiers in Medicine 13 , no. 3 (2019): 388–397.
110 L. Kazantseva , J. Becerra , and L. Santos‐Ruiz , “Oridonin Enhances Antitumor Effects of Doxorubicin in Human Osteosarcoma Cells,” Pharmacological Reports 74 , no. 1 (2022): 248–256.34427908
111 N. Kang , S. Cao , B. Jiang , et al., “Cetuximab Enhances Oridonin‐Induced Apoptosis Through Mitochondrial Pathway and Endoplasmic Reticulum Stress in Laryngeal Squamous Cell Carcinoma Cells,” Toxicology In Vitro 67 (2020): 104885.32407876
112 X. Liang , J. Yao , D. Cui , et al., “The TRAF2‐p62 Axis Promotes Proliferation and Survival of Liver Cancer by Activating mTORC1 Pathway,” Cell Death and Differentiation 30 , no. 6 (2023): 1550–1562.37081115
113 C. Xi , S. Peng , Z. Wu , Q. Zhou , and J. Zhou , “Toxicity of Triptolide and the Molecular Mechanisms Involved,” Biomedicine & Pharmacotherapy 90 (2017): 531–541.28402922
114 P. Li , X. Yang , Y. Yang , et al., “Synergistic Effect of all‐Trans‐Retinal and Triptolide Encapsulated in an Inflammation‐Targeted Nanoparticle on Collagen‐Induced Arthritis in Mice,” Journal of Controlled Release 319 (2020): 87–103.31862360
115 K. Yuan , X. Li , Q. Lu , et al., “Application and Mechanisms of Triptolide in the Treatment of Inflammatory Diseases‐A Review,” Frontiers in Pharmacology 10 (2019): 1469.31866868
116 B. Tang , J. Zhu , B. Zhang , et al., “Therapeutic Potential of Triptolide as an Anti‐Inflammatory Agent in Dextran Sulfate Sodium‐Induced Murine Experimental Colitis,” Frontiers in Immunology 11 (2020): 592084.33240279
117 Y. Cheng , Y. Zhao , and Y. Zheng , “Therapeutic Potential of Triptolide in Autoimmune Diseases and Strategies to Reduce Its Toxicity,” Chinese Medicine 16 , no. 1 (2021): 114.34743749
118 X. Zhao , X. Tang , Q. Yan , et al., “Triptolide Ameliorates Lupus via the Induction of miR‐125a‐5p Mediating Treg Upregulation,” International Immunopharmacology 71 (2019): 14–21.30861393
119 X. Zhai , L. Wang , C. Xu , et al., “Triptolide Preserves Glomerular Barrier Function via the Inhibition of p53‐Mediated Increase of GADD45B,” Archives of Biochemistry and Biophysics 671 (2019): 210–217.31330131
120 L. Zhao , Z. Lan , L. Peng , et al., “Triptolide Promotes Autophagy to Inhibit Mesangial Cell Proliferation in IgA Nephropathy via the CARD9/p38 MAPK Pathway,” Cell Proliferation 55 , no. 9 (2022): e13278.35733381
121 Z. He , B. O. A. Botchway , Y. Zhang , and X. Liu , “Triptolide Activates the Nrf2 Signaling Pathway and Inhibits the NF‐κB Signaling Pathway to Improve Alzheimer Disease,” Metabolic Brain Disease 39 (2023): 173–182.37624431
122 P. Yao , Y. Li , Y. Yang , S. Yu , and Y. Chen , “Triptolide Improves Cognitive Dysfunction in Rats With Vascular Dementia by Activating the SIRT1/PGC‐1α Signaling Pathway,” Neurochemical Research 44 , no. 8 (2019): 1977–1985.31236795
123 R. Yücer , S. Fayez , D. Feineis , et al., “Cytotoxicity of Dioncophylline A and Related Naphthylisoquinolines in Leukemia Cells, Mediated by NF‐κB Inhibition, Angiogenesis Suppression, G2/M Cell Cycle Arrest, and Autophagy Induction,” Phytomedicine 126 (2024): 155267.38368795
124 P. Chen , P. Zhao , M. Hu , et al., “HnRNP A2/B1 as a Potential Anti‐Tumor Target for Triptolide Based on a Simplified Thermal Proteome Profiling Method Using XGBoost,” Phytomedicine 117 (2023): 154929.37329754
125 V. Liskova , M. Kajsik , B. Chovancova , L. Roller , and O. Krizanova , “Camptothecin, Triptolide, and Apoptosis Inducer kit Have Differential Effects on Mitochondria in Colorectal Carcinoma Cells,” FEBS Open Bio 12 , no. 5 (2022): 913–924.
126 B. J. Philips , A. Kumar , S. Burki , J. P. Ryan , K. Noda , and J. D'Cunha , “Triptolide‐Induced Apoptosis in Non‐small Cell Lung Cancer via a Novel miR204‐5p/Caveolin‐1/Akt‐Mediated Pathway,” Oncotarget 11 , no. 28 (2020): 2793–2806.32733649
127 Y. Shi , H. Zhao , J. Ye , et al., “Low‐Dose Triptolide Enhances Antitumor Effect of JQ1 on Acute Myeloid Leukemia Through Inhibiting RNA Polymerase II In Vitro and In Vivo,” Molecular Carcinogenesis 59 , no. 9 (2020): 1076–1087.32691884
128 Q. Tian , P. Zhang , Y. Wang , et al., “A Novel Triptolide Analog Downregulates NF‐κB and Induces Mitochondrial Apoptosis Pathways in Human Pancreatic Cancer,” eLife 12 (2023): 12.
129 J. Cai , M. Yi , Y. Tan , et al., “Natural Product Triptolide Induces GSDME‐Mediated Pyroptosis in Head and Neck Cancer Through Suppressing Mitochondrial Hexokinase‐ΙΙ,” Journal of Experimental & Clinical Cancer Research 40 , no. 1 (2021): 190.34108030
130 X. Wu , S. Chen , K. Huang , and G. Lin , “Triptolide Promotes Ferroptosis by Suppressing Nrf2 to Overcome Leukemia Cell Resistance to Doxorubicin,” Molecular Medicine Reports 27 (2023): 17.36453238
131 M. Dodson , R. Castro‐Portuguez , and D. D. Zhang , “NRF2 Plays a Critical Role in Mitigating Lipid Peroxidation and Ferroptosis,” Redox Biology 23 (2019): 101107.30692038
132 E. Borazanci , A. Saluja , J. Gockerman , et al., “First‐In‐Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity,” The Oncologist 29 , no. 2 (2024): 132–141.38169017
133 Y. Hu , Q. Wu , Y. Wang , et al., “The Molecular Pathogenesis of Triptolide‐Induced Hepatotoxicity,” Frontiers in Pharmacology 13 (2022): 979307.36091841
134 M. Hasnat , Z. Yuan , A. Ullah , et al., “Mitochondria‐Dependent Apoptosis in Triptolide‐Induced Hepatotoxicity Is Associated With the Drp1 Activation,” Toxicology Mechanisms and Methods 30 , no. 2 (2020): 124–133.31557070
135 L. Zhang , J. Zhou , Z. Feng , et al., “Qingluo Tongbi Formula Alleviates Hepatotoxicity Induced by Tripterygium wilfordii Hook. F. By Regulating Excessive Mitophagy Through the PERK‐ATF4 Pathway,” Frontiers in Pharmacology 13 (2022): 918466.35873540
136 M. Hasnat , Z. Yuan , M. Naveed , et al., “Drp1‐Associated Mitochondrial Dysfunction and Mitochondrial Autophagy: A Novel Mechanism in Triptolide‐Induced Hepatotoxicity,” Cell Biology and Toxicology 35 , no. 3 (2019): 267–280.30542779
137 F. Shen , Z. Xiong , J. Kong , et al., “Triptolide Impairs Thioredoxin System by Suppressing Notch1‐Mediated PTEN/Akt/Txnip Signaling in Hepatocytes,” Toxicology Letters 300 (2019): 105–115.30394310
138 W. Xing , G. Liu , Y. Zhang , T. Zhang , H. Lou , and P. Fan , “Selective Antitumor Effect and Lower Toxicity of Mitochondrion‐Targeting Derivatization of Triptolide,” Journal of Medicinal Chemistry 67 , no. 2 (2024): 1093–1114.38169372
139 A. Saneja , D. Arora , R. Kumar , R. D. Dubey , A. K. Panda , and P. N. Gupta , “Therapeutic Applications of Betulinic Acid Nanoformulations,” Annals of the New York Academy of Sciences 1421 , no. 1 (2018): 5–18.29377164
140 R. H. Cichewicz and S. A. Kouzi , “Chemistry, Biological Activity, and Chemotherapeutic Potential of Betulinic Acid for the Prevention and Treatment of Cancer and HIV Infection,” Medicinal Research Reviews 24 , no. 1 (2004): 90–114.14595673
141 W. Jiang , X. Li , S. Dong , and W. Zhou , “Betulinic Acid in the Treatment of Tumour Diseases: Application and Research Progress,” Biomedicine & Pharmacotherapy 142 (2021): 111990.34388528
142 J. F. Oliveira‐Costa , C. S. Meira , M. Neves , et al., “Anti‐Inflammatory Activities of Betulinic Acid: A Review,” Frontiers in Pharmacology 13 (2022): 883857.35677426
143 A. Del Pozo , L. Silva , A. Romero , et al., “Neuroprotective Effects of Betulinic Acid Hydroxamate in Intraventricular Hemorrhage‐Induced Brain Damage in Immature Rats,” Nutrients 14 , no. 24 (2022): 5286.36558445
144 J. L. C. Sousa , C. Gonçalves , R. M. Ferreira , et al., “Functionalization of Betulinic Acid With Polyphenolic Fragments for the Development of New Amphiphilic Antioxidants,” Antioxidants 10 , no. 2 (2021): 148.33498465
145 D. Lee , S. R. Lee , K. S. Kang , et al., “Betulinic Acid Suppresses Ovarian Cancer Cell Proliferation Through Induction of Apoptosis,” Biomolecules 9 , no. 7 (2019): 257.31277238
146 H. Wang , F. Dong , Y. Wang , et al., “Betulinic Acid Induces Apoptosis of Gallbladder Cancer Cells via Repressing SCD1,” Acta Biochimica et Biophysica Sinica Shanghai 52 , no. 2 (2020): 200–206.
147 H. Zhang , M. Zhou , C. Ye , et al., “Betulinic Acid Inhibits the Proliferation of Human Laryngeal Carcinoma Cells Through Reactive Oxygen Species‐Mediate Mitochondrial Apoptotic Pathway,” Toxicology In Vitro 95 (2023): 105756.38061603
148 A. Zeng , H. Hua , L. Liu , and J. Zhao , “Betulinic Acid Induces Apoptosis and Inhibits Metastasis of Human Colorectal Cancer Cells in Vitro and in Vivo,” Bioorganic & Medicinal Chemistry 27 , no. 12 (2019): 2546–2552.30910472
149 S. Y. Kim , H. Hwangbo , M. Y. Kim , et al., “Betulinic Acid Restricts Human Bladder Cancer Cell Proliferation in Vitro by Inducing Caspase‐Dependent Cell Death and Cell Cycle Arrest, and Decreasing Metastatic Potential,” Molecules 26 , no. 5 (2021): 1381.33806566
150 P. Sharma and S. Kumar , “Metformin Inhibits Human Breast Cancer Cell Growth by Promoting Apoptosis via a ROS‐Independent Pathway Involving Mitochondrial Dysfunction: Pivotal Role of Superoxide Dismutase (SOD),” Cellular Oncology (Dordrecht) 41 , no. 6 (2018): 637–650.
151 N. Yao , C. Wang , N. Hu , et al., “Inhibition of PINK1/Parkin‐Dependent Mitophagy Sensitizes Multidrug‐Resistant Cancer Cells to B5G1, a New Betulinic Acid Analog,” Cell Death & Disease 10 , no. 3 (2019): 232.30850585
152 A. García‐González , J. M. Espinosa‐Cabello , I. Cerrillo , et al., “Bioavailability and Systemic Transport of Oleanolic Acid in Humans, Formulated as a Functional Olive oil,” Food & Function 14 , no. 21 (2023): 9681–9694.37812020
153 J. Pollier and A. Goossens , “Oleanolic Acid,” Phytochemistry 77 (2012): 10–15.22377690
154 J. Liu , “Pharmacology of Oleanolic Acid and Ursolic Acid,” Journal of Ethnopharmacology 49 , no. 2 (1995): 57–68.8847885
155 M. Alqrad , D. S. El‐Agamy , S. R. M. Ibrahim , et al., “SIRT1/Nrf2/NF‐κB Signaling Mediates Anti‐Inflammatory and Anti‐Apoptotic Activities of Oleanolic Acid in a Mouse Model of Acute Hepatorenal Damage,” Medicina (Kaunas, Lithuania) 59 , no. 7 (2023): 1351.37512162
156 M. Kalaskar , V. Redasani , M. Ayyanar , et al., “Isolation and Characterization of Anti‐Inflammatory Compounds From Ficus microcarpa L.f. Stem Bark,” Plants 12 , no. 18 (2023): 3248.37765413
157 Y. Ban , Y. Chu , F. Pan , et al., “Lipid‐Based Nanocarriers Enabled Oral Delivery of Oleanolic Acid Derivative DKS26 for Diabetes Management,” Advanced Healthcare Materials 12 , no. 16 (2023): e2300639.36977335
158 J. Cui , E. Shi , Y. Wang , and T. Liu , “Network Pharmacology Study of the Mechanism Underlying the Therapeutic Effect of Zhujing Pill and Its Main Component Oleanolic Acid Against Diabetic Retinopathy,” Bioscience Reports 43 , no. 1 (2023): BSR20220893.36714956
159 J. Liu , J. Liu , C. Meng , et al., “NRF2 and FXR Dual Signaling Pathways Cooperatively Regulate the Effects of Oleanolic Acid on Cholestatic Liver Injury,” Phytomedicine 108 (2023): 154529.36343550
160 X. Lin , Q. Zhou , L. Zhou , et al., “Quinoa (Chenopodium quinoa Willd) Bran Saponins Alleviate Hyperuricemia and Inhibit Renal Injury by Regulating the PI3K/AKT/NFκB Signaling Pathway and Uric Acid Transport,” Journal of Agricultural and Food Chemistry 71 , no. 17 (2023): 6635–6649.37083411
161 H. Jo , J. H. Oh , D. W. Park , C. Lee , and C. K. Min , “Oleanolic Acid 3‐Acetate, a Minor Element of Ginsenosides, Induces Apoptotic Cell Death in Ovarian Carcinoma and Endometrial Carcinoma Cells via the Involvement of a Reactive Oxygen Species‐Independent Mitochondrial Pathway,” Journal of Ginseng Research 44 , no. 1 (2020): 96–104.32095097
162 F. Jannus , M. Medina‐O'donnell , F. Rivas , et al., “A Diamine‐PEGylated Oleanolic Acid Derivative Induced Efficient Apoptosis Through a Death Receptor and Mitochondrial Apoptotic Pathway in HepG2 Human Hepatoma Cells,” Biomolecules 10 , no. 10 (2020): 1375.32998255
163 L. Tian , H. Ji , W. Wang , et al., “Mitochondria‐Targeted Pentacyclic Triterpenoid Carbon Dots for Selective Cancer Cell Destruction via Inducing Autophagy, Apoptosis, as Well as Ferroptosis,” Bioorganic Chemistry 130 (2023): 106259.36375351
164 I. Potočnjak , L. Šimić , I. Vukelić , L. Batičić , and R. Domitrović , “Oleanolic Acid Induces HCT116 Colon Cancer Cell Death Through the p38/FOXO3a/Sirt6 Pathway,” Chemico‐Biological Interactions 363 (2022): 110010.35690101
165 S. Hosny , H. Sahyon , M. Youssef , and A. Negm , “Oleanolic Acid Suppressed DMBA‐Induced Liver Carcinogenesis Through Induction of Mitochondrial‐Mediated Apoptosis and Autophagy,” Nutrition and Cancer 73 , no. 6 (2021): 968–982.32519911
166 W. Zhou , X. Zeng , and X. Wu , “Effect of Oleanolic Acid on Apoptosis and Autophagy of SMMC‐7721 Hepatoma Cells,” Medical Science Monitor 26 (2020): e921606.32424110
167 C. Gao , X. Li , S. Yu , and L. Liang , “Inhibition of Cancer Cell Growth by Oleanolic Acid in Multidrug Resistant Liver Carcinoma Is Mediated via Suppression of Cancer Cell Migration and Invasion, Mitochondrial Apoptosis, G2/M Cell Cycle Arrest and Deactivation of JNK/p38 Signalling Pathway,” Journal of BUON 24 , no. 5 (2019): 1964–1969.31786862
168 M. Bian , Y. Sun , Y. Liu , et al., “A Gold(I) Complex Containing an Oleanolic Acid Derivative as a Potential Anti‐Ovarian‐Cancer Agent by Inhibiting TrxR and Activating ROS‐Mediated ERS,” Chemistry 26 , no. 31 (2020): 7092–7108.32037581
169 H. Nakamura and K. Takada , “Reactive Oxygen Species in Cancer: Current Findings and Future Directions,” Cancer Science 112 , no. 10 (2021): 3945–3952.34286881
170 J. Liese , T. M. Hinrichs , M. Lange , and S. Fulda , “Cotreatment With Sorafenib and Oleanolic Acid Induces Reactive Oxygen Species‐Dependent and Mitochondrial‐Mediated Apoptotic Cell Death in Hepatocellular Carcinoma Cells,” Anti‐Cancer Drugs 30 , no. 3 (2019): 209–217.30640794
171 B. Cheng , X. Chu , R. Liu , et al., “Synthesis of Novel Pentacyclic Triterpenoid Derivatives That Induce Apoptosis in Cancer Cells Through a ROS‐Dependent, Mitochondrial‐Mediated Pathway,” Molecular Pharmaceutics 20 , no. 1 (2023): 701–710.36458832
172 A. T. Mbaveng , G. F. Chi , I. N. Bonsou , et al., “N‐Acetylglycoside of Oleanolic Acid (Aridanin) Displays Promising Cytotoxicity Towards Human and Animal Cancer Cells, Inducing Apoptotic, Ferroptotic and Necroptotic Cell Death,” Phytomedicine 76 (2020): 153261.32559584
173 W. Ju , N. Li , J. Wang , et al., “Design and Synthesis of Novel Mitochondria‐Targeted CDDO Derivatives as Potential Anti‐Cancer Agents,” Bioorganic Chemistry 115 (2021): 105249.34390971
174 Y. Li , Q. Zeng , R. Wang , et al., “Synthesis and Discovery of Mitochondria‐Targeting Oleanolic Acid Derivatives for Potential PI3K Inhibition,” Fitoterapia 162 (2022): 105291.36064154
